QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
NYSE:TEVA

Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

$12.78
-0.40 (-3.03%)
(As of 04:35 PM ET)
Today's Range
$12.75
$13.21
50-Day Range
$12.01
$14.44
52-Week Range
$7.09
$14.47
Volume
8.95 million shs
Average Volume
10.69 million shs
Market Capitalization
$14.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.78

Teva Pharmaceutical Industries MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
7.4% Upside
$13.78 Price Target
Short Interest
Healthy
1.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of Teva Pharmaceutical Industries in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$5.13 M Sold Last Quarter
Proj. Earnings Growth
10.09%
From $2.28 to $2.51 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.54 out of 5 stars

Medical Sector

686th out of 914 stocks

Pharmaceutical Preparations Industry

310th out of 413 stocks

TEVA stock logo

About Teva Pharmaceutical Industries Stock (NYSE:TEVA)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

TEVA Stock Price History

TEVA Stock News Headlines

Teva Pharmaceutical Industries (NYSE:TEVA) Trading Down 5.3%
Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...
Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...
25 Countries with the Lowest Fertility Rates
TEVA Mar 2024 20.000 call
Teva Pharma Industries Ltd ADR (TEVAy)
TEVA Mar 2024 12.000 put
TEVA Mar 2024 13.000 call
See More Headlines
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/31/2024
Today
4/18/2024
Next Earnings (Confirmed)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
37,851
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.78
High Stock Price Target
$19.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+4.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$-559,000,000.00
Pretax Margin
-3.94%

Debt

Sales & Book Value

Annual Sales
$15.85 billion
Cash Flow
$3.55 per share
Book Value
$7.25 per share

Miscellaneous

Outstanding Shares
1,121,090,000
Free Float
1,114,143,000
Market Cap
$14.79 billion
Optionable
Optionable
Beta
1.05
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

TEVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TEVA shares.
View TEVA analyst ratings
or view top-rated stocks.

What is Teva Pharmaceutical Industries' stock price target for 2024?

10 brokers have issued 1 year target prices for Teva Pharmaceutical Industries' stock. Their TEVA share price targets range from $10.00 to $19.00. On average, they anticipate the company's share price to reach $13.78 in the next year. This suggests a possible upside of 7.4% from the stock's current price.
View analysts price targets for TEVA
or view top-rated stocks among Wall Street analysts.

How have TEVA shares performed in 2024?

Teva Pharmaceutical Industries' stock was trading at $10.44 on January 1st, 2024. Since then, TEVA shares have increased by 22.9% and is now trading at $12.83.
View the best growth stocks for 2024 here
.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 10,460,000 shares, a drop of 28.9% from the February 29th total of 14,720,000 shares. Based on an average trading volume of 10,530,000 shares, the short-interest ratio is presently 1.0 days.
View Teva Pharmaceutical Industries' Short Interest
.

When is Teva Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TEVA earnings forecast
.

How can I listen to Teva Pharmaceutical Industries' earnings call?

Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, May 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) released its quarterly earnings data on Wednesday, January, 31st. The company reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.73 by $0.25. The firm earned $4.46 billion during the quarter, compared to the consensus estimate of $3.97 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 34.90% and a negative net margin of 3.33%.

What ETFs hold Teva Pharmaceutical Industries' stock?

ETFs with the largest weight of Teva Pharmaceutical Industries (NYSE:TEVA) stock in their portfolio include VanEck Israel ETF (ISRA), iShares MSCI Israel ETF (EIS), VanEck Pharmaceutical ETF (PPH) and ARK Israel Innovative Technology ETF (IZRL).iShares MSCI Intl Size Factor ETF (ISZE).

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY24 earnings guidance on Wednesday, January, 31st. The company provided earnings per share (EPS) guidance of $2.20-$2.50 for the period, compared to the consensus earnings per share estimate of $2.41. The company issued revenue guidance of $15.7-$16.3 billion, compared to the consensus revenue estimate of $15.57 billion.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Top institutional investors include IMC Chicago LLC (0.00%), Hennion & Walsh Asset Management Inc. (0.02%), Range Financial Group LLC (0.01%), Atlas Capital Advisors LLC (0.00%), Park Avenue Securities LLC (0.00%) and Banque Cantonale Vaudoise (0.00%). Insiders that own company stock include Amir Weiss, David Matthew Stark, Eli Shani, Eliyahu Sharon Kalif, Eric A Hughes, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard D Francis, Sven Dethlefs and Vikki L Conway.
View institutional ownership trends
.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:TEVA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners